These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34525328)

  • 1. Effects of COVID-19 on preclinical and clinical research in neurology: Examples from research on neurodegeneration and Alzheimer's disease.
    Snider BJ; Holtzman DM
    Neuron; 2021 Oct; 109(20):3199-3202. PubMed ID: 34525328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How COVID-19 has transformed my science.
    Iwasaki A
    Neuron; 2021 Oct; 109(19):3041-3044. PubMed ID: 34363752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Military risk factors for Alzheimer's dementia and neurodegenerative disease.
    Khachaturian AS; Khachaturian ZS
    Alzheimers Dement; 2014 Jun; 10(3 Suppl):S90-1. PubMed ID: 24924677
    [No Abstract]   [Full Text] [Related]  

  • 4. Research during the SARS-CoV-2 pandemic.
    Muñoz de Nova JL; Ortega-Gómez M; Abad-Santos F;
    Med Clin (Barc); 2021 Jan; 156(1):39-40. PubMed ID: 33268132
    [No Abstract]   [Full Text] [Related]  

  • 5. Creating a transatlantic research enterprise for preventing Alzheimer's disease.
    Khachaturian ZS; Camí J; Andrieu S; Avila J; Boada Rovira M; Breteler M; Froelich L; Gauthier S; Gómez-Isla T; Khachaturian AS; Kuller LH; Larson EB; Lopez OL; Martinez-Lage JM; Petersen RC; Schellenberg GD; Sunyer J; Vellas B; Bain LJ
    Alzheimers Dement; 2009 Jul; 5(4):361-6. PubMed ID: 19560106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of Alzheimer's disease: general methodological aspects].
    Gauthier S
    Rev Neurol (Paris); 2004 Feb; 160(2):261-4. PubMed ID: 15034487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19: a catalyst for flexibility and creativity in neurology.
    The Lancet Neurology
    Lancet Neurol; 2020 Jul; 19(7):557. PubMed ID: 32562669
    [No Abstract]   [Full Text] [Related]  

  • 8. Alzheimer's disease and other dementias: update on research.
    Schneider L
    Lancet Neurol; 2017 Jan; 16(1):4-5. PubMed ID: 27979354
    [No Abstract]   [Full Text] [Related]  

  • 9. Viewpoint: Impact of the Covid-19 Outbreak on the Clinical and Research Activities of Memory Clinics: An Alzheimer's Disease Center Facing the Covid-19 Crisis.
    Ousset PJ; Vellas B
    J Prev Alzheimers Dis; 2020; 7(3):197-198. PubMed ID: 32463074
    [No Abstract]   [Full Text] [Related]  

  • 10. The Toulouse Gérontopôle Research Center: report of activities, 2007-2011.
    Gillette-Guyonnet S; Vellas B
    J Alzheimers Dis; 2012; 28(3):721-32. PubMed ID: 22258518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tsuneya Ikezu.
    Lancet Neurol; 2017 Jan; 16(1):31. PubMed ID: 27979352
    [No Abstract]   [Full Text] [Related]  

  • 12. The Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC).
    Kupersmith MJ; Miller N; Balcer L; Gordon L; Wall M; Keltner J; Friedman D; Feldon S; McDermott M; Kieburtz K
    J Neuroophthalmol; 2009 Sep; 29(3):259-61. PubMed ID: 19726952
    [No Abstract]   [Full Text] [Related]  

  • 13. Translational research in neurology: dementia.
    Honig LS
    Arch Neurol; 2012 Aug; 69(8):969-77. PubMed ID: 22473767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosome Biomarkers Revolutionize Preclinical Diagnosis of Neurodegenerative Diseases and Assessment of Treatment Responses in Clinical Trials.
    Kapogiannis D
    Adv Exp Med Biol; 2020; 1195():149. PubMed ID: 32468469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2021 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2021 Mar; 17(3):327-406. PubMed ID: 33756057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Alzheimer Precision Medicine Initiative.
    Hampel H; Vergallo A; Perry G; Lista S;
    J Alzheimers Dis; 2019; 68(1):1-24. PubMed ID: 30814352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.
    Mills SM; Mallmann J; Santacruz AM; Fuqua A; Carril M; Aisen PS; Althage MC; Belyew S; Benzinger TL; Brooks WS; Buckles VD; Cairns NJ; Clifford D; Danek A; Fagan AM; Farlow M; Fox N; Ghetti B; Goate AM; Heinrichs D; Hornbeck R; Jack C; Jucker M; Klunk WE; Marcus DS; Martins RN; Masters CM; Mayeux R; McDade E; Morris JC; Oliver A; Ringman JM; Rossor MN; Salloway S; Schofield PR; Snider J; Snyder P; Sperling RA; Stewart C; Thomas RG; Xiong C; Bateman RJ
    Rev Neurol (Paris); 2013 Oct; 169(10):737-43. PubMed ID: 24016464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Link of COVID-19 and Neurodegenerative Disorders.
    Kamal MA
    CNS Neurol Disord Drug Targets; 2022; 21(3):208-209. PubMed ID: 35040398
    [No Abstract]   [Full Text] [Related]  

  • 19. Advances of Alzheimer's disease research: crossroad of basic and translational studies.
    Lahiri DK
    Curr Alzheimer Res; 2005 Dec; 2(5):495-6. PubMed ID: 16375652
    [No Abstract]   [Full Text] [Related]  

  • 20. Alemtuzumab and the value of neurological research.
    Lancet Neurology
    Lancet Neurol; 2014 Mar; 13(3):233. PubMed ID: 24556003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.